Quick answer: In the published rat studies cited here, Semax was applied intranasally as a single 50 µg/kg application, daily at 0.05 mg/kg during early life, and in a spinal-cord injury model. One paper found intranasal administration more potent than intraperitoneal for a learning task. This guide reports those parameters and explains the unit arithmetic. It recommends nothing. Laboratory research use only.
What this article is, and is not
"Semax intranasal" is a popular search, and many pages that answer it drift into advice. This one does not. It is a laboratory-content guide: it states what published preclinical studies reported about intranasal administration of Semax in rodents, and it explains how a researcher converts those reported figures into a stock solution and a per-animal volume. It does not recommend an amount, a schedule or a use in any person or animal outside a research protocol, and every figure below belongs to the paper it came from.
The material discussed is the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, supplied by V8 Peptides as a 15 mg lyophilized research vial, formula C37H51N9O10S, stated purity at least 98% by HPLC; see the Semax product page. Background is in the Semax research overview.
Why the nasal route appears in the literature
Intranasal administration is common in rodent neuropharmacology because it is non-invasive, can be repeated, and is widely used for peptides studied in the brain. In the Semax papers it is used for single applications in gene-expression work, for repeated applications in developmental models and for acute application after injury. The route is a design choice, not a statement of mechanism, and the one head-to-head comparison in the set shows the choice can change the result.
Parameters reported in the published studies
| Study | Species and model | Route and amount as reported | Schedule | Readout |
|---|---|---|---|---|
| Agapova et al. [1] | Male Wistar rats, normal brain | Intranasal, 50 µg/kg | Single application, analysis at 1 h | Ngf and Bdnf mRNA by real-time PCR |
| Dolotov et al. [2] | Rats, hippocampus | Intranasal, 50 µg/kg | Single application | BDNF protein, trkB phosphorylation, mRNA; conditioned avoidance |
| Manchenko et al. [3] | White rats | Intranasal and intraperitoneal, several amounts | Not detailed in abstract | Passive avoidance; paw-withdrawal pain test |
| Volodina et al. [4] | White rats, neonatal maternal deprivation | Intranasal, 0.05 mg/kg | Daily, postnatal days 15 to 28 | Body mass, anxiety-type behavior |
| Asadullah et al. [5] | Male Sprague-Dawley rats, spinal cord injury | Intranasal | Tissue taken at 3 and 6 h | IL-4, IL-10, IL-13 immunohistochemistry |
The first two rows use the same per-kilogram figure, which makes cross-reading easy. The route comparison is the most informative for design: following intranasal administration, Semax was reported to be more potent in learning improvement than intraperitoneal administration, while intraperitoneal but not intranasal administration affected pain sensitivity [3]. In the spinal-cord injury model, intranasal Semax was reported to give greater anti-inflammatory cytokine levels at 3 hours in mild injury, with IL-10 and IL-13 elevated significantly at 6 hours, and different cytokine patterns in severe injury [5]. The abstract notes the control group received 0.9% NaCl.
For comparison, a chronic stress study administered a low amount of Semax intraperitoneally, reported in nanomoles per kilogram (60 nmol/kg daily) [6], and an acute-stress paper gave 100 µg/kg 30 minutes before restraint (the route is not stated in the abstract) [7]. Reading the literature therefore means moving between µg/kg, mg/kg and nmol/kg.
Unit arithmetic: formula only
Three conversions cover almost every case. These are formulas; they are not recommendations.
| Goal | Formula |
|---|---|
| Stock concentration | Vial mass (mg) ÷ diluent volume (mL) = mg/mL |
| Amount per animal | Reported amount (µg/kg) × animal body mass (kg) = µg |
| Volume per animal | Amount per animal (µg) ÷ stock concentration (µg/µL) = µL |
| nmol/kg to µg/kg | nmol/kg × molar mass (g/mol) ÷ 1000 = µg/kg |
Molar mass comes from the formula. For C37H51N9O10S, summing standard atomic weights gives about 813.9 g/mol for the free peptide. By that arithmetic, 60 nmol/kg corresponds to about 48.8 µg/kg and 50 µg/kg corresponds to about 61 nmol/kg, which shows that the 50 µg/kg intranasal papers and the 60 nmol/kg intraperitoneal paper used similar per-kilogram quantities even though they are written in different units. Counter-ions and residual water mean the weighed mass of a lyophilized powder is not all peptide, so a lab that needs exact peptide content should confirm it analytically. The reconstitution calculator handles the concentration step, and the peptide reconstitution volume calculations article walks through the arithmetic.
Practical issues specific to intranasal work in animals
Intranasal application in a rodent is physical work. The volume that fits on the nasal epithelium is small, so concentration has to be high enough that the needed amount fits in that volume; this is why papers state amounts and not volumes, and why the arithmetic above matters. Animals must be handled gently and consistently, because stress from restraint can alter the very readouts being measured, and the vehicle-only group must be handled identically. Hydration, anesthesia and head position all change how much reaches the epithelium and how much is swallowed. None of these are Semax-specific, and none can be read from an abstract, so a laboratory should consult the full methods of the paper it is replicating.
Preparing the stock
The product page states storage at 2–8 °C, with −20 °C for long-term storage, protected from heat, moisture and light. The sequence carries an N-terminal methionine that can oxidize in solution, so stocks are kept cold and sealed, and single-use portions are frozen rather than one vial being refrozen. Sterile diluent is the usual choice for a multi-use vial. Let the diluent run down the wall, let the powder wet and swirl gently without shaking. If the experiment is sensitive to benzyl alcohol, a preservative-free diluent is an alternative, with the stock divided into portions the same day. The how to reconstitute a lyophilized peptide guide covers the general method, and the bacteriostatic water explained article describes the diluent choice.
Quality documentation belongs in the experiment record: lot identifier, purity, test date. The COA page explains where batch documentation is published, and the how to read a COA guide explains what each field means.
A reading checklist for any intranasal paper
Before relying on a published intranasal figure, a laboratory can run a short checklist against the paper's full text, because abstracts rarely carry the details that decide reproducibility.
- Amount basis. Is the figure per kilogram of body mass or per animal? Is it peptide mass or salt-form mass?
- Vehicle. Saline, buffer or another carrier, and whether the control received the same volume.
- Volume and application. Total volume, drops per nostril, interval between drops, and whether the animal was conscious or anesthetized.
- Timing. Interval between application and the measurement, and between repeated applications.
- Animal details. Strain, sex, age, body mass range, housing, light cycle.
- Handling of controls. Whether control animals were handled and restrained the same way.
- Analysis. Number of animals per group, blinding and statistics used.
A paper that answers all of these is replicable; a paper that leaves several blank is best regarded as a hint about what is possible and not a template. The checklist also guards against a common drift: moving a figure from one paper into another model (a different strain, age or injury) and assuming the same amount means the same exposure.
Reporting your own intranasal work
Mirror the checklist when writing up. State the stock concentration and how it was made, the lot identifier of the vial, the storage history of the stock (how long in solution, how many freeze–thaw cycles), and the per-animal amount and volume actually delivered. Those details cost a few lines and make the difference between a result that others can build on and one they cannot interpret.
What the intranasal literature does not settle
It does not give a dose-response relationship for intranasal Semax; the reported amounts are few and chosen by each group for its own model. It does not establish bioavailability to the brain, because the abstracts cited report effects, not tissue concentrations. It does not show that results transfer to other species. The overlap among authoring groups limits independence. The correct use of this literature is as a catalog of what was done, not a protocol to copy. For the sibling peptide, see Selank and Semax compared, and browse the shop for related research materials.
Frequently asked questions
What amount was used in the intranasal rat studies?
Two papers used a single application of 50 µg/kg. Another used 0.05 mg/kg daily from postnatal day 15 to 28. These are the papers' own figures, not recommendations.
Was the intranasal route better than intraperitoneal?
In one rat study, the intranasal route was reported to be more potent for learning improvement, while only the intraperitoneal route affected pain sensitivity.
How do I convert µg/kg into a volume?
Multiply by the animal's body mass in kilograms to get micrograms per animal, then divide by the stock concentration in µg/µL.
How do I convert nmol/kg into µg/kg?
Multiply by the molar mass in g/mol and divide by 1000. For C37H51N9O10S the molar mass computed from the formula is about 813.9 g/mol.
How do I calculate stock concentration?
Divide vial mass in mg by diluent volume in mL. The site calculator does this and is the place to check the result.
Why do papers report amounts rather than volumes?
The nasal volume is small and varies with the protocol, so the amount per kilogram is the portable quantity.
How should the vial be stored?
At 2–8 °C, or −20 °C for long-term storage, protected from heat, moisture and light.
Does the methionine matter?
Methionine can oxidize in solution, so stocks are kept cold and sealed and divided into single-use portions.
Do these studies show brain levels of the peptide?
The abstracts cited report effects on expression, behavior or cytokines, not measured tissue concentrations.
Is this a guide for use outside a laboratory?
No. It lists parameters reported in published animal studies, and the product is sold for laboratory research only.
Research-use statement
This product is supplied for laboratory research use only. It is not a drug, food or cosmetic, and it is not for human or animal consumption. This article reports published preclinical parameters without recommending them. Browse the research library for related articles.
Related reading: Semax in Ischemia Models: What Mechanism Studies Show, Semax in Animal Models: A Model Selection Guide, Semax as a Nootropic Peptide: Reading the Research.
References
- Agapova TY, Agniullin YV, Shadrina MI, Shram SI, Slominsky PA, Lymborska SA, et al. Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH4–10. Neuroscience Letters. 2007;417(2):201-205. doi:10.1016/j.neulet.2007.02.042
- Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, et al. Semax, an analog of ACTH(4–10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006;1117(1):54-60. doi:10.1016/j.brainres.2006.07.108
- Manchenko DM, et al. Nootropic and analgesic effects of Semax following different routes of administration. Ross Fiziol Zh Im I M Sechenova. 2010. PMID: 21268834
- Volodina MA, Sebentsova EA, Glazova NY, Levitskaya NG, Andreeva LA, Manchenko DM, et al. Semax Attenuates the Infl uence of Neonatal Maternal Deprivation on the Behavior of Adolescent White Rats. Bull Exp Biol Med. 2012;152(5):560-563. doi:10.1007/s10517-012-1574-2
- Asadullah A, Bajamal AH, Parenrengi MA, Turchan A, Utomo B, Sudiana IK, et al. Effect of ACTH4-10Pro8-Gly9-Pro10 on anti-inflammatory cytokine (IL-4, IL-10, IL-13) expression in acute spinal cord injury models (male Sprague Dawley rats). F1000Res. 2025;12:194. doi:10.12688/f1000research.127413.2
- Inozemtseva LS, Yatsenko KA, Glazova NY, Kamensky AA, Myasoedov NF, Levitskaya NG, et al. Antidepressant-like and antistress effects of the ACTH(4–10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress. European Journal of Pharmacology. 2024;984:177068. doi:10.1016/j.ejphar.2024.177068
- Filippenkov IB, Stavchansky VV, Glazova NY, Sebentsova EA, Remizova JA, Valieva LV, et al. Antistress Action of Melanocortin Derivatives Associated with Correction of Gene Expression Patterns in the Hippocampus of Male Rats Following Acute Stress. IJMS. 2021;22(18):10054. doi:10.3390/ijms221810054
